Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
I think their production of the drug is subject to demand available at the time. Synairgen is a small company and they would want to ensure that there are some guaranrtees of income before they commit to full scale production. Otherwise they can go bust.
This is why they said that the upscaling to 100000 doses a month is dependent on government support. This means that if any government places advance orders they will increase the output to match.
If they manufacture this amount without any guarantee they can become bankrupt. It is common sense approach to managing a business.
The video is dated October 2020 and they have recruited 775 patients for the Phase 3 trial and the results expected very soon. Our tial with 600 odd patients is not far behind. The speed of recruitment seem to be similar for both studies. Does anyone know the actual dates of their study?
Government support is mentioned in the following statement.
'As a result, the Company expects to have tens of thousands of treatment courses available to the market should an EUA be granted. With government support, the Company has the potential to increase capacity to approximately 100,000 treatment courses per month.'
This can mean two things.
1. The company has resources to manufacture tens of thousands of doses with current resources
2. The company will only scale up if the government places advance orders.
I think 2 is the most likely answer.
https://www.standard.co.uk/news/uk/covid-coronavirus-latest-updates-ronapreve-treatment-sajid-javid-travel-list-tests-news-b951524.html
Have they completed Phase 3? Why is Sajit promoting this?
The presentation slides did not show any significant positive effects of the use of SNG 001 on patients form the home trial. This is because the severity of the desease was not significant. This is different from what I originally thought.
In order to put a positive spin they borrowed the results of hospital study to show the extent of improvement in severe cases. Up to 80% of the patients data came from the hospital trial to show this improvement.
The reality now is that the drug appears to work in severe cases in hospital environment. We need to wait another 6 months to prove this. The market size is also now much less than I originally assumed.
I think the article relates to patients in ICUs only. There has been other reports that show that Interferons can have a negative impact at later stages of Covid 19.
This is a known fact and our trial SNG018 is not intended for patients in ICUs.
Peel
All I did was to change the last 2 letters in the following link from PT to GB.
https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004743-83/PT
PT stands for Portugal and therefore I tested link again with replacement letters GB and it produced the data fro GB showing the patient numbers as 200 for UK. The tota number of patients seem to be 900 in this page. I know this is now out of date because the total number is now reduced to around 600. This is why I think the pages are not up to date. I tested other countries as well but only some abbreviations work.
I just checked the link andthe last 2 charaters shows the country. In this link PT stands for portugal with 50 patients. If you change PT to GB you get data sheet for UK. However I think the data in these links are out of date.
Do we still have supply/availability issuea for SNG001? Only trialled at a restricted number of US sites?
Quoted in the document dated 22 /12/2020.
Page 216
SITES PARTICIPATING IN THE STUDY
Participation in phase II evaluations of this agent will be restricted to select US sites, due to
limited investigational agent/placebo supply.
How can we meet demand if we still have supply problems?
I think it is a very risky decision not to take any available treatment for early stages of Covid 19 such as SNG001.
Normal flue you can sit it out but not Covid 19. This is because Covid 19 causes long term damage to your lungs which may take up to 15 years to completely recover.
Even with a mild infection your lung capacity reduces and you will feel tired for many years to come until your lung capacity improves.
When more people realise this drugs like SNG001 will be the choice people will opt for.
Dont forget if you are investing in an AIMS company such as Synairgen then there are other tax benefits such as exemptions from CGT and Inheritance tax. More details in the link below.
https://aim-watch.com/project/aim-tax-benefits/